Alpine Immune Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALPN research report →
Companywww.alpineimmunesciences.com
Alpine Immune Sciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.
- CEO
- Mitchell H. Gold
- IPO
- 2015
- Employees
- 142
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $4.46B
- P/E
- -100.94
- P/S
- 75.70
- P/B
- 9.91
- EV/EBITDA
- -140.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -37.41%
- Op Margin
- -75.16%
- Net Margin
- -54.66%
- ROE
- -12.69%
- ROIC
- -13.06%
Growth & Income
- Revenue
- $58.88M · 95.84%
- Net Income
- $-32,184,000 · 44.28%
- EPS
- $-0.64 · 63.01%
- Op Income
- $-44,250,000
- FCF YoY
- -80.00%
Performance & Tape
- 52W High
- $65.00
- 52W Low
- $8.33
- 50D MA
- $52.49
- 200D MA
- $26.27
- Beta
- 0.97
- Avg Volume
- 2.37M
Get TickerSpark's AI analysis on ALPN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 24 | Peetz Christopher | sell | 7,650 |
| May 20, 24 | Peetz Christopher | sell | 17,500 |
| May 20, 24 | Peetz Christopher | sell | 10,000 |
| May 20, 24 | Peetz Christopher | sell | 7,650 |
| May 20, 24 | Peetz Christopher | sell | 7,650 |
| May 20, 24 | Peetz Christopher | sell | 10,000 |
| May 20, 24 | Peetz Christopher | sell | 7,650 |
| May 20, 24 | Peetz Christopher | sell | 1,900 |
| May 20, 24 | Hernday Natasha | sell | 10,000 |
| May 20, 24 | Hernday Natasha | sell | 10,000 |
Our ALPN Coverage
We haven't published any research on ALPN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALPN Report →